drugset / Trial / NCT03508869
Mirvaso® Gel and Dysport® for Erythema and Flushing of Rosacea
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of Mirvaso® Gel and Dysport® for erythema and flushing of Rosacea.
Timeline
- Start
- 2016-09-27
- Primary completion
- 2017-09-20
- Completion
- 2017-09-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | — | — |
| Comparator | Brimonidine | Small molecule | 0.33 % | Topical |